Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04774237 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
A Phase 2 study, sponsored by Visus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT04774237: Completed Phase 2 study, sponsored by Visus Therapeutics.
NCT04774237 is a Phase 2 study that has completed, run by Visus Therapeutics. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04774237, a Phase 2 study, has completed, sponsored by Visus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia
Primary Outcome
Primary Endpoint measured at Hour 1 post-dose at Study Visit - a Single drop Cohort
Interventions
- DRUG BRIMOCHOL™
- DRUG BRIMOCHOL™ F
- DRUG Carbachol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2021-10-19 |
| Phase | Phase 2 |
What the finished NCT04774237 record still lists
NCT04774237 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which BRIMOCHOL™ is the first listed.
NCT04774237 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04774237 about?
NCT04774237 is a clinical study titled "Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia". Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia
What is the current status of trial NCT04774237?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-03-24. Estimated completion is 2021-10-19.
What interventions are being tested in trial NCT04774237?
The interventions under investigation include: BRIMOCHOL™ (DRUG), BRIMOCHOL™ F (DRUG), Carbachol (DRUG).
Who is sponsoring clinical trial NCT04774237?
This trial is sponsored by Visus Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04774237's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI